Biblio

Author Title [ Type

] Year

Filters: Author is Boissel, Nicolas [Clear All Filters]

Journal Article

Topp MS, Stein AS, Gökbuget N, Horst H-A, Boissel N, Martinelli G, Kantarjian H, Brüggemann M, Chen Y, Zugmaier G. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Cancer Med. 2021.

Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti A-M, Sebert M, Boissel N, Robin M, Vey N, Kiladjian J-J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.

Kiesewetter B, Cherny NI, Boissel N, Cerisoli F, Dafni U, de Vries EGE, Ghia P, Gökbuget N, González-Calle V, Huntly B, et al. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5(1).

Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023;11(8).

Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021.

Caillot L, Leclerc M, Sleiman EJacques Ra, Sloma I, Wagner-Ballon O, Claudel A, Beckerich F, Redjoul R, Robin C, Parinet V, et al. Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study. Haematologica. 2023.

Chevillon F, Clappier E, Arfeuille C, Cayuela J-M, Dalle J-H, Kim R, Caye A, Chalas C, Abdo C, Drouineaud V, et al. Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia. Blood. 2020.

Chalandon Y, Rousselot P, Chevret S, Cayuela J-M, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie SP, et al. Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia. Blood. 2024.

Laetsch TW, Myers GDouglas, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, de Moerloose B, Davis KL, Nemecek E, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019.

Dombret H, Cluzeau T, Huguet F, Boissel N. Pediatric-Like Therapy for Adults with ALL. Curr Hematol Malig Rep. 2014.

Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, Fortin G, Meslin P-A, Yakoub-Agha I, Sujobert P, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.

Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.